Eton Pharmaceuticals Inc Cash Flow Conversion Efficiency
Eton Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Eton Pharmaceuticals Inc (ETON) has a cash flow conversion efficiency ratio of 0.156x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($7.25 Million) by net assets ($46.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Eton Pharmaceuticals Inc (2017–2025)
Cash flow conversion efficiency of Eton Pharmaceuticals Inc from 2017 to 2025. This chart illustrates how Eton Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Eton Pharmaceuticals Inc share price for real-time trading data and today's change.
Eton Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Eton Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Eton Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eton Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see ETON market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Quantum Computing Inc
NASDAQ:QUBT
|
-0.007x |
|
Shanghai Qiangsheng Holding Co Ltd
SHG:600662
|
0.122x |
|
TGS ASA SP.ADR/1
F:TGC0
|
0.129x |
|
Tibet Mineral Development Co Ltd
SHE:000762
|
0.009x |
|
Weichai Heavy Machinery Co Ltd
SHE:000880
|
0.131x |
|
Atrium Ljungberg AB (publ)
ST:ATRLJ-B
|
0.005x |
|
Befesa SA
XETRA:BFSA
|
0.044x |
|
Dominos PIZZA Enterprises Ltd
AU:DMP
|
0.148x |
Annual Cash Flow Conversion Efficiency for Eton Pharmaceuticals Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Eton Pharmaceuticals Inc from 2017 to 2025. Review cash generation quality of Eton Pharmaceuticals Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $26.15 Million | $10.52 Million | 0.402x | +914.39% |
| 2024-12-31 | $24.43 Million | $969.00K | 0.040x | -90.99% |
| 2023-12-31 | $15.48 Million | $6.82 Million | 0.440x | +19.45% |
| 2022-12-31 | $13.08 Million | $4.82 Million | 0.369x | +237.66% |
| 2021-12-31 | $17.63 Million | $-4.72 Million | -0.268x | +81.23% |
| 2020-12-31 | $15.66 Million | $-22.35 Million | -1.427x | +16.50% |
| 2019-12-31 | $10.55 Million | $-18.03 Million | -1.709x | -451.77% |
| 2018-12-31 | $26.30 Million | $-8.14 Million | -0.310x | +20.39% |
| 2017-12-31 | $12.13 Million | $-4.72 Million | -0.389x | -- |
About Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for … Read more